Cargando…
Strategies to Overcome Resistance to Immune-Based Therapies in Osteosarcoma
Improving the prognosis and cure rate of HGOSs (high-grade osteosarcomas) is an absolute need. Immune-based treatment approaches have been increasingly taken into consideration, in particular for metastatic, relapsed and refractory HGOS patients, to ameliorate the clinical results currently achieved...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9821333/ https://www.ncbi.nlm.nih.gov/pubmed/36614241 http://dx.doi.org/10.3390/ijms24010799 |
_version_ | 1784865671567376384 |
---|---|
author | Hattinger, Claudia Maria Salaroglio, Iris Chiara Fantoni, Leonardo Godel, Martina Casotti, Chiara Kopecka, Joanna Scotlandi, Katia Ibrahim, Toni Riganti, Chiara Serra, Massimo |
author_facet | Hattinger, Claudia Maria Salaroglio, Iris Chiara Fantoni, Leonardo Godel, Martina Casotti, Chiara Kopecka, Joanna Scotlandi, Katia Ibrahim, Toni Riganti, Chiara Serra, Massimo |
author_sort | Hattinger, Claudia Maria |
collection | PubMed |
description | Improving the prognosis and cure rate of HGOSs (high-grade osteosarcomas) is an absolute need. Immune-based treatment approaches have been increasingly taken into consideration, in particular for metastatic, relapsed and refractory HGOS patients, to ameliorate the clinical results currently achieved. This review is intended to give an overview on the immunotherapeutic treatments targeting, counteracting or exploiting the different immune cell compartments that are present in the HGOS tumor microenvironment. The principle at the basis of these strategies and the possible mechanisms that HGOS cells may use to escape these treatments are presented and discussed. Finally, a list of the currently ongoing immune-based trials in HGOS is provided, together with the results that have been obtained in recently completed clinical studies. The different strategies that are presently under investigation, which are generally aimed at abrogating the immune evasion of HGOS cells, will hopefully help to indicate new treatment protocols, leading to an improvement in the prognosis of patients with this tumor. |
format | Online Article Text |
id | pubmed-9821333 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-98213332023-01-07 Strategies to Overcome Resistance to Immune-Based Therapies in Osteosarcoma Hattinger, Claudia Maria Salaroglio, Iris Chiara Fantoni, Leonardo Godel, Martina Casotti, Chiara Kopecka, Joanna Scotlandi, Katia Ibrahim, Toni Riganti, Chiara Serra, Massimo Int J Mol Sci Review Improving the prognosis and cure rate of HGOSs (high-grade osteosarcomas) is an absolute need. Immune-based treatment approaches have been increasingly taken into consideration, in particular for metastatic, relapsed and refractory HGOS patients, to ameliorate the clinical results currently achieved. This review is intended to give an overview on the immunotherapeutic treatments targeting, counteracting or exploiting the different immune cell compartments that are present in the HGOS tumor microenvironment. The principle at the basis of these strategies and the possible mechanisms that HGOS cells may use to escape these treatments are presented and discussed. Finally, a list of the currently ongoing immune-based trials in HGOS is provided, together with the results that have been obtained in recently completed clinical studies. The different strategies that are presently under investigation, which are generally aimed at abrogating the immune evasion of HGOS cells, will hopefully help to indicate new treatment protocols, leading to an improvement in the prognosis of patients with this tumor. MDPI 2023-01-02 /pmc/articles/PMC9821333/ /pubmed/36614241 http://dx.doi.org/10.3390/ijms24010799 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Hattinger, Claudia Maria Salaroglio, Iris Chiara Fantoni, Leonardo Godel, Martina Casotti, Chiara Kopecka, Joanna Scotlandi, Katia Ibrahim, Toni Riganti, Chiara Serra, Massimo Strategies to Overcome Resistance to Immune-Based Therapies in Osteosarcoma |
title | Strategies to Overcome Resistance to Immune-Based Therapies in Osteosarcoma |
title_full | Strategies to Overcome Resistance to Immune-Based Therapies in Osteosarcoma |
title_fullStr | Strategies to Overcome Resistance to Immune-Based Therapies in Osteosarcoma |
title_full_unstemmed | Strategies to Overcome Resistance to Immune-Based Therapies in Osteosarcoma |
title_short | Strategies to Overcome Resistance to Immune-Based Therapies in Osteosarcoma |
title_sort | strategies to overcome resistance to immune-based therapies in osteosarcoma |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9821333/ https://www.ncbi.nlm.nih.gov/pubmed/36614241 http://dx.doi.org/10.3390/ijms24010799 |
work_keys_str_mv | AT hattingerclaudiamaria strategiestoovercomeresistancetoimmunebasedtherapiesinosteosarcoma AT salaroglioirischiara strategiestoovercomeresistancetoimmunebasedtherapiesinosteosarcoma AT fantonileonardo strategiestoovercomeresistancetoimmunebasedtherapiesinosteosarcoma AT godelmartina strategiestoovercomeresistancetoimmunebasedtherapiesinosteosarcoma AT casottichiara strategiestoovercomeresistancetoimmunebasedtherapiesinosteosarcoma AT kopeckajoanna strategiestoovercomeresistancetoimmunebasedtherapiesinosteosarcoma AT scotlandikatia strategiestoovercomeresistancetoimmunebasedtherapiesinosteosarcoma AT ibrahimtoni strategiestoovercomeresistancetoimmunebasedtherapiesinosteosarcoma AT rigantichiara strategiestoovercomeresistancetoimmunebasedtherapiesinosteosarcoma AT serramassimo strategiestoovercomeresistancetoimmunebasedtherapiesinosteosarcoma |